Lipocine NASH data contain plenty of ‘red flags,’ STAT’s Feuerstein writes

This morning’s eight-week top-line interim results for Lipocine’s LPCN 1144 in non-alcoholic steatohepatitis contain plenty of “red flags” and do not hold up to scrutiny, STAT’s Adam Feuerstein writes in a new report. Shares of Lipocine are up 31%, or 49c, to $2.08 in midday trading.

https://thefly.com/landingPageNews.php?id=2850439